BeStock  
Stocks › Biotechnology › BCAX

Bicara Therapeutics BCAX

US equityMarket cap rank #3530Biotechnology
$8.44 −$0.68 (-7.46%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.44 0.00%
Open$8.83
Prev close$9.12
Day range$8.43 – $9.14
Volume814.5K
Market cap$560.31M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership110.2%-6.93 pts vs. prior quarter
Institutions holding203-10 vs. prior quarter
Insider trades (recent)10 buys / 40 sellsNet selling
Short interest14.90% of floatDays to cover 3.8 · as of 30 Oct 2026
Short-sale volume share23.2%5-day average of daily volume

Short-sale volume as % of daily volume

4%13%22%32%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$3.12M (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

+$2.3MSuper+$804.3KBig+$2.0MMid+$1.3MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 42.5% of shares outstanding.

Largest holders

  • RA Capital Management, L.P.10.93%
  • Biocon Limited8.32%
  • Artal Group S.A.8.29%
  • Vestal Point Capital, LP7.91%
  • T. Rowe Price Group, Inc.7.09%
  • Deep Track Capital, LP6.18%
  • BlackRock5.94%
  • Janus Henderson Group plc4.78%

By investor type

  • Mutual Fund41.78%
  • VC/PE Fund41.01%
  • Hedge Fund15.45%
  • Public Company10.40%
  • Individual/Insider1.83%
  • Private Company0.79%
  • Endowment Fund0.43%
  • Government Pension Fund0.14%

Reported short interest has fallen from 15.81% to 14.90% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Franklin Resources Mutual Fund 2026/Q3 +713,245 4.0%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +195,191 1.0%
Citigroup Inc. Public Company 2026/Q3 +142,329 0.3%
BlackRock Mutual Fund 2026/Q3 +97,404 5.9%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +82,279 0.1%
UBS Asset Management Mutual Fund 2026/Q3 +67,946 0.2%
Tema ETFs LLC Mutual Fund 2026/Q3 +38,259 0.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +90,637 0.1%
BlackRock Mutual Fund 2026/Q3 +1,004,383 5.8%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +828,979 1.5%
State Street Global Advisors Mutual Fund 2026/Q3 +629,532 3.1%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +539,405 3.8%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +352,463 0.7%
Franklin Resources Mutual Fund 2026/Q3 +346,166 2.9%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +331,729 1.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
20 Oct 2026 David Raben Former Chief Medical Officer Intent to Sell (Form 144) -24,777 $18.12 –
7 Sep 2026 Ryan Cohlhepp President Derivative Exercise and Sale -17,500 $23.43 181,641
7 Sep 2026 Ivan Hyep Former Chief Financial Officer Intent to Sell (Form 144) -12,500 $22.64 –
9 Aug 2026 Ryan Cohlhepp President Derivative Exercise and Sale -18,750 $27.98 181,641
9 Aug 2026 Claire Mazumdar Clemon Chief Executive Officer Derivative Exercise and Sale -10,000 $27.98 362,152
9 Aug 2026 Ivan Hyep Former Chief Financial Officer Derivative Exercise and Sale -12,500 $27.97 129,855
27 Jul 2026 Christy Oliger Independent Director Other Derivative Acquisition +38,950 $26.88 38,950
27 Jul 2026 Jeremy Bender Independent Director Other Derivative Acquisition +38,950 $26.88 38,950
9 Jul 2026 Claire Mazumdar Clemon Chief Executive Officer Derivative Exercise and Sale -10,000 $29.68 362,152
8 Jul 2026 Ryan Cohlhepp President Automatic Disposition -10,000 $30.35 181,641
7 Jul 2026 Ryan Cohlhepp President Derivative Exercise and Sale -18,750 $28.76 181,641
7 Jul 2026 David Raben Former Chief Medical Officer Intent to Sell (Form 144) -50,000 $28.56 –
7 Jul 2026 Ivan Hyep Former Chief Financial Officer Automatic Disposition -15,500 $30.31 129,855
7 Jul 2026 Ivan Hyep Former Chief Financial Officer Derivative Exercise and Sale -12,500 $28.60 129,855
24 Jun 2026 David Raben Former Chief Medical Officer Intent to Sell (Form 144) -50,000 $26.49 –
8 Jun 2026 Michael Powell Independent Chairperson Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Kiran Mazumdar-Shaw Former Independent Director Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 RA Capital Management, L.P. Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Scott Robertson Independent Director Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Christopher Bowden Independent Director Other Derivative Acquisition +19,475 $20.56 19,475

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 9,861,807 14.9% 3.8
15 Oct 2026 10,298,207 15.6% 11.5
30 Sep 2026 10,693,490 16.2% 14.2
15 Sep 2026 11,191,724 16.9% 22.6
31 Aug 2026 10,845,514 16.4% 22.1
14 Aug 2026 10,463,188 15.8% 13.3

Discussion

No comments yet — be the first to weigh in on BCAX.

Sign in to join the discussion.

Scroll to Top